The KIF1B Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma line, engineered to disrupt the KIF1B gene. This pooled polyclonal population provides a loss-of-function model for studying the kinesin motor protein KIF1B without requiring single-cell cloning, preserving heterogeneity that may more closely reflect natural biological variation. The product enables investigation of KIF1B??s roles in microtubule-based transport, apoptosis, and tumor suppression within a well-characterized cancer cell context.
HeLa cells are an immortalized epithelial cell line originating from cervical adenocarcinoma, constitutively expressing human papillomavirus type 18 (HPV18) oncoproteins. The viral E6 protein inhibits p53, while E7 degrades the retinoblastoma protein (pRB), resulting in deregulated cell cycle progression and enhanced genomic instability. This genetic background renders HeLa cells a versatile platform for studying oncogenic signaling, apoptosis resistance, and intracellular trafficking. Their robust growth characteristics and extensive historical use in biomedical research provide a reliable host for generating stable knockout models.
KIF1B encodes a plus-end-directed kinesin motor protein that transports cargoes including mitochondria along microtubules. Two major isoforms exist: KIF1B?? is essential for mitochondrial trafficking and ATP distribution, while KIF1B?? is a tumor suppressor that interacts with dynein light chain DLC1 to activate the intrinsic apoptotic pathway. In the context of NGF/TrkA signaling, KIF1B?? functions downstream of TrkA and MAPKs, relaying pro-apoptotic signals that promote mitochondrial cytochrome c release and caspase-3 activation. Additionally, KIF1B?? activity is modulated by CaMKII phosphorylation and 14-3-3 protein binding, linking calcium signaling to motor function. Knockout of KIF1B disrupts these signaling nodes, impairing both mitochondrial localization and programmed cell death machinery.
In HeLa cells, which naturally exhibit dysregulated apoptosis due to p53 inactivation and HPV oncogene expression, ablation of KIF1B provides a unique model to dissect alternative cell death pathways. The loss of KIF1B??-mediated tumor suppressor activity in an already transformed context may reveal compensatory mechanisms or sensitize cells to chemotherapeutic agents. Furthermore, disruption of KIF1B??-dependent mitochondrial trafficking alters organelle distribution, which can affect metabolic fitness and migration capacity. Researchers can use this model to examine the intersection of cytoskeletal transport and apoptotic sensitivity, particularly how mitochondrial positioning influences cytochrome c release and caspase activation under stress conditions.
Typical applications include studying mitochondrial dynamics through live-cell imaging and immunofluorescence, assessing apoptotic responses via Annexin V staining and caspase-3 activity assays, and investigating tumor suppression by examining cell migration and invasion. Co-immunoprecipitation experiments can validate the loss of KIF1B-DLC1 interactions, while Western blotting confirms absence of KIF1B isoforms. This polyclonal knockout cell product is a valuable tool for research in cancer biology, neuropathies such as Charcot-Marie-Tooth disease type 2A1, and neuronal transport modeling. For inquiries, please contact Ascent Research.
